The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.

about

The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.

Item

http://www.wikidata.org/entity/Q47118947

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@en

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@nl

type

Item

label

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@en

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@nl

prefLabel

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@en

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@nl

P1476

The Nonvitamin K Antagonist Or ...... Challenges and Considerations.

@en

P2093

Anna Plitt

http://www.w3.org/2001/XMLSchema#string

Sameer Bansilal

http://www.w3.org/2001/XMLSchema#string

P2860

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Dabigatran versus warfarin in patients with atrial fibrillation

Idarucizumab for Dabigatran Reversal

Dabigatran versus warfarin in patients with mechanical heart valves

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Edoxaban versus warfarin in patients with atrial fibrillation

Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.

Initial 3-weeks' Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) followed by Clopidogrel alone in high-risk patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): study protocol for a randomized controlled trial.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

P304

1547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.4022/JAFIB.1547

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29250278

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

5673394

http://www.w3.org/2001/XMLSchema#string